Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Rheumatology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location from dropdown

Polymyalgia Rheumatica (PMR) Clinical Trials

A listing of Polymyalgia Rheumatica (PMR) medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (6) clinical trials

Safety and Efficacy of tocilizuMAb Versus Placebo in Polymyalgia rHeumatica With glucocORticoid dEpendence SEMAPHORE

Patients are treated with infusions of Tocilizumab (TCZ) or placebo for 5 months. Clinical evaluation is performed using PMR-AS. The PMR-AS is computed by summing the 5 variables after multiplying by 0.1 for weighting purposes: PMR-AS (activity scale = AS) = C reactive protein (CRP) (mg/dl) + patient scale (VASp) ...

Phase

A Study to Evaluate the Efficacy of Tocilizumab as a Remission-Induction and Glucocorticoid-Sparing Regimen in Subjects With New-Onset Polymyalgia Rheumatica (PMR- SPARE)

Background. Polymyalgia rheumatica is an inflammatory rheumatic disease of the elderly, with a usually rapid response to intermediate-doses of glucocorticoids (GCs). In many patients, relapses occur upon its dose reduction or cessation. Given the patients' age and the adverse event profile of GCs, steroid- free remission is the most desired ...

Phase

Evaluation of the Efficacy and Safety of Sarilumab in Patients With Polymyalgia Rheumatica

Study duration per participant is approximative 62 weeks including up to a 4-week screening period, 52-week treatment period and 6-week follow-up period.

Phase

Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity

This case control study aims to determine whether spontaneous coronary artery dissection (SCAD) is associated with autoimmune diseases and to update the incidence of SCAD in a population-based cohort.

Phase N/A

Abatacept in earLy Onset Polymyalgia Rheumatica: Study ALORS

Polymyalgia rheumatic (PMR) is a frequent inflammatory disease. It affects the elderly, with peak incidences at the age of 70 to 80 years; an age >50 years or older, is considered a criterion for the diagnosis. Polymyalgia rheumatica occurs at a frequency that is 3 to 10 times that of ...

Phase

Treatment With Leflunomide in Patients With Polymyalgia Rheumatica

Over the last decades outcome has greatly improved for rheumatoid arthritis (RA) and spondyloarthritis (SpA). This is in sharp contrast to the situation for polymyalgia rheumatica (PMR), with a lifetime prevalence of 2.4% for women and 1.7% for men, PMR is the commonest auto-inammatory musculoskeletal disease in adults aged 50 ...

Phase